#Chronic Idiopathic Constipation Treatment Market report

[soumyafwr]

https://biiut.com/read-blog/56294_global-chronic-idiopathic-constipation-treatment-market-size-overview-key-player.html

Chronic Idiopathic Constipation Treatment Market 

[vijayanger12]

The report, the global chronic idiopathic constipation treatment market was valued over US$ 7.8 Bn in 2021. It is projected to expand at a CAGR of ~7% from 2022 to 2030

[jesse-pinkman123]

Peptide-Based Gastrointestinal Disorders Therapeutics Market Analysis-2027

Peptide-Based Gastrointestinal Disorders Therapeutics Market Regional Analysis

North America Peptide-Based Gastrointestinal Disorders Therapeutics Market is expected to exhibit good growth over the forecast period, owing to presence of major players and adoption of strategies such as mergers and collaborations by them for novel peptide-based therapeutics. For instance, in February 2018, Cipher Pharmaceuticals Inc. acquired exclusive Canadian rights of the U.S. Food and Drug Administration approved drug Trulance (plecanatide) from Synergy Pharmaceuticals Inc. After the acquisition, Cipher Pharmaceuticals Inc. will develop, market, distribute, and sell Trulance (plecanatide) in the Canadian Market.

Asia Pacific peptide-based gastrointestinal disorders therapeutics market is expected to exhibit significant growth over the forecast period, owing to increasing investments made by players in the region to receive approval of novel peptide-based therapeutics. For instance, in 2014, Ironwood Pharmaceuticals, Inc. received US$ 15 million from Astellas Pharma Inc., a Japan-based pharmaceutical company, for initiating Phase III clinical trial of Linzess (linaclotide) in Japan, and receive its approval from Japanese Ministry of Health, Labor, and Welfare in 2016. Ironwood Pharmaceuticals, Inc. and Astellas Pharma Inc. were under strategic partnership since 2009 for developing and commercializing linaclotide in Japan.

Peptides are short chains of amino acid monomers linked by peptide (amide) bonds. Peptide-based gastrointestinal (GIT) disorders therapeutics are drugs that are used for the treatment of various GIT disorders such as short bowel syndrome, chronic constipation, and irritable bowel syndrome. In the recent past, some peptide-based therapeutics such as Trulance, Linaclotide, and Teduglutide received approval for the treatment of GIT disorders.

* The sample copy includes: Report Summary, Table of Contents, Segmentation, Competitive Landscape, Report Structure, Methodology.

Request a sample copy of this report: https://www.coherentmarketinsights.com/insight/request-sample/2028

Trulance is a guanylate cyclase-C agonist indicated for the treatment of chronic idiopathic constipation in adults. Linaclotide is a 14 amino acid peptide that acts as an agonist of guanylate cyclase C receptors in the intestine. It is a minimally absorbed agonist of guanylate cyclase C receptors in the intestine and is used for the treatment of chronic constipation and irritable bowel syndrome. Teduglutide is a new recombinant analogue for glucagon-like peptide (GLP) -2, a natural occurring peptide, which is secreted primarily by the lower gastrointestinal tract.

Peptide-Based Gastrointestinal Disorders Therapeutics Market Dynamics

Frequent approval and launch of novel peptide-based gastrointestinal disorders therapeutics in key regions is expected to drive the global peptide-based gastrointestinal disorders therapeutics market growth over the forecast period.

For instance, in 2017, Synergy Pharmaceuticals Inc. received the U.S. Food and Drug Administration (FDA) approval for its new drug TRULANCE (plecanatide) 3 mg tablet. This drug is indicated for the treatment of irritable bowel syndrome with constipation (IBS-C) in adults.

In 2012, Ironwood Pharmaceuticals, Inc. and Forest Laboratories, Inc. received the U.S. Food and Drug Administration approval for its drug called Linzess (linaclotide). Linzess (linaclotide) is a guanylate cyclase-C agonist used for the treatment of adults suffering from irritable bowel syndrome with constipation (IBS-C) and chronic idiopathic constipation (CIC).

Browse Research Report: https://www.coherentmarketinsights.com/ongoing-insight/peptide-based-gastrointestinal-disorders-therapeutics-market-2028

In 2016, Ironwood Pharmaceuticals, Inc.’s partner, Astellas Pharma Inc., received marketing approval from the Japanese Ministry of Health, Labor, and Welfare for Linzess (linaclotide), and in 2017, Astellas Pharma Inc. launched Linzess (linaclotide) in Japan.

In 2012, NPS Pharmaceuticals, Inc. received approval from the U.S. Food and Drug Administration (FDA) for its drug Gattex (Teduglutide (rDNA origin)). Gattex 0.05 mg/kg/d injection is a new, recombinant analog of human glucagon-like peptide 2, a protein involved in the rehabilitation of the intestinal lining. It is indicated for the treatment of adult patients with short bowel syndrome (SBS) who are dependent on parenteral support. Sucg frequent approval is expected to cather peptide-based gastrointestinal disorders therapeutics market growth in near future.

Furthermore, increasing prevalence of gastrointestinal disorders is expected to rise the demand for peptide-based drugs, which will in turn drive the global peptide-based gastrointestinal disorders therapeutics market growth. For instance, according to the data published by the International Foundation for Functional Gastrointestinal Disorder in 2016, irritable bowel syndrome (IBS) is the most common functional gastrointestinal (GI) disorder and globally, around 10-15% of the population suffers from IBS.

Peptide-Based Gastrointestinal Disorders Therapeutics Market Key Players

Key players operating in the global peptide-based gastrointestinal disorders therapeutics market include Ironwood Pharmaceuticals, Inc., NPS Pharmaceuticals, Inc., Synergy Pharmaceuticals Inc., Astellas Pharma Inc., Allergan plc., and Cipher Pharmaceuticals Inc.

Buy-Now this research report: https://www.coherentmarketinsights.com/insight/buy-now/2028

About Coherent Market Insights:            

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

Contact Us:

mailto:sales@coherentmarketinsights.com

U.S. Office:

Name:  Mr. Shah

Coherent Market Insights 1001 4th Ave,

# 3200 Seattle, WA 98154, U.S.

US :  +1-206-701-6702

UK :  +44-020-8133-4027

JAPAN :  +050-5539-1737

[wiseguyreportresearch]

Global Opioid-Induced Constipation Treatment MarketAnalysis, Historic Data and Forecast 2020

Opioid-Induced Constipation Treatment Market Reports

Global Opioid-Induced Constipation Treatment Market are the drugs used for its pain relieving properties in non-cancer and chronic pain. The adverse effects associated with the opioids are decreasing gastrointestinal tract’s motility, making patient’s strain, and making of solid discharges. Furthermore, long-term use of opioids cause harm to the sensory system, limits the release of endogenous opioids such as endorphins. Adults are most likely to prone to opioid-induced constipation owing to less immobility, poor diet, and fluid intake. The symptoms associated with the opioid-induced constipation are included dry and hard tools, leathery feeling, painful defecation, bulged abdomen, and loss of appetite.

ALSO READ : https://icrowdnewswire.com/2021/01/06/opioid-induced-constipation-treatment-industry-treatment-outlook-analysis-research-review-to-2023/

The opioid-induced constipation treatment market growing at a significant CAGR due to rise in the aging population using opioid analgesics for chronic pains. Increase in the illicit use of medications, prolonged usage of opioids in the treatment of pain, an increase in the prevalence of cancer is anticipated to boost the global opioid-induced constipation treatment market. Furthermore, launching of newer drugs, growing FDA approvals, positive outcomes in clinical trials, and rise in the healthcare expenditure are expected to propel the opioid-induced constipation treatment market over the forecast period. However, lack of awareness regarding opioid-induced constipation in patients, the absence of treatment innovations, a high cost of newer pharmaceuticals, adverse effects, including nausea, a risk of heart problems and strokes associated with these drugs and unfavorable reimbursement policies expected to hamper the growth of the opioid-induced constipation treatment market.

ALSO READ : http://www.marketwatch.com/story/specialty-insurance-market-key-players-industry-size-trend-share-and-global-growth-opportunities-forecast-to-2026-2021-01-29

The opioid-induced constipation treatment market is segmented on the basis of drug type, formulation type, route of administration, and distribution channel

Based on drug type, opioid-induced constipation treatment market has been segmented into the following

Peripherally restricted μ-opioid receptor antagonists

Non-selective opioid antagonists

μ -opioid receptor antagonists

Locally acting chloride channel activators

Based on formulation type, opioid-induced constipation treatment market has been segmented into the following

Solids

Semi-solids

Liquids

Based on route of administration, opioid-induced constipation treatment market has been segmented into the following

Oral

Parenteral (Subcutaneous Injection)

Based on distribution channel, opioid-induced constipation treatment market has been segmented into the following

Drugstore

Retail pharmacies

Hospital pharmacies

ALSO READ :http://www.marketwatch.com/story/car-rental-market-2021-industry-size-share-price-trend-and-forecast-to-2026-2021-01-27

The Global Opioid-Induced Constipation Treatment Market is in the growing stage, several players are actively engaged in the development of the opioid-induced constipation treatment market products. Major acquisitions and collaborations among companies to commercialize opioid-induced constipation treatment market products to drive the market growth. For instance, in March 2015, the co-commercialization agreement for Movenpick signed by AstraZeneca and Daiichi Sankyo, and in October 2014, the entry of Takeda and Sucampo into a global licensing, development, and commercialization agreement for Amitiza are expected to boost the global opioid-induced constipation treatment market. Launching of new products, approval of new drugs from various regulatory bodies, and pipeline products under clinical trials are the key factors fuelling the growth of the opioid-induced constipation treatment market. For instance, Linaclotide was approved by the FDA in August 2012 and by the European Medicines Agency for the treatment in adults with constipation-predominant irritable bowel syndrome and chronic idiopathic constipation.

Geographically, Global Opioid-Induced Constipation Treatment Market has been segmented into following regions Viz. North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa. North America holds the largest share in the opioid-induced constipation treatment market followed by Europe and Asia-Pacific. North America holds the largest share due to expanding the base of opioid-induced constipation patients, According to the American Society of Interventional Pain Physician, in 2013, the U.S. alone was responsible for nearly 80% of the global consumption of opioids. Europe accounts for the significant share in the opioid-induced constipation treatment market owing to increased demand for opioid analgesics in various European countries such as UK, France, Spain, Germany etc. However, growing elderly population in India and China, and rise in healthcare spending are creating the huge growth opportunity for the players in Asia-Pacific region. Apart from that, Latin America and the Middle East are the potential areas for the growth of opioid-induced constipation treatment market because of the increase in opioid-induced constipation sufferers.

ALSO READ : http://www.marketwatch.com/story/global-hydropower-generation-market-industry-analysis-size-share-growth-trends-and-forecast-2021-2027-2021-01-23

Some of the players in the opioid-induced constipation treatment market are GlaxoSmithKline plc (U.K.), AstraZeneca U.K), Pfizer Inc. (U.S.), SLA Pharma AG (U.K.), AIKO Biotechnology, Inc. (U.S.), Cubist Pharmaceuticals (Merck & Co.) (U.S.), Takeda Pharmaceutical Company Limited (Japan), Boehringer Ingelheim GmbH (Germany), Bayer AG (Germany), Valeant Pharmaceuticals International Inc. (Canada), Abbott Laboratories (U.S.), Purdue Pharma LP (U.S.) Shionogi Inc. (U.S.) and Cosmo Pharmaceuticals N.V. (Ireland) to name a few.

In March 2017, FDA approved Symphonic (Naldemedine) for the treatment of Opioid-Induced Constipation, which was manufactured by Purdue Pharma LP and Shionogi

In March 2016, AstraZeneca announced that it has entered into an agreement with ProStrakan Group, a subsidiary of Kyowa Hakko Kirin Co. Ltd., for the rights to Moventig (Naloxegol) in the European Union (EU)

Report Outline:

The report provides granular level information about the market size, regional market share, and forecast from 2017-2023

The report covers in-detail insights about the competitor’s overview, key findings, and their key strategies

The report outlines drivers, restraints, challenges, and trends that are currently faced by the industry

The report tracks recent innovations, key developments and startup’s details that are working in the industry

The report provides plethora of information about market entry strategies, regulatory framework and reimbursement scenario

ALSO READ : http://www.marketwatch.com/story/global-female-skincare-market-projection-by-latest-technology-opportunity-application-growth-services-project-revenue-analysis-report-forecast-to-2026-2021-01-19

[dbmronkar]

Global ELISA Tests Market is Rising Market to Rapidly Growing $2529.27 million by 2026 with Top Key Players Ortho Clinical Diagnostics, Thermo Fisher Scientific, ZEUS Scientific,  ALPCO, Bio-Rad Laboratories, bioMérieux, Merck KGaA,  BioLegend, LOEWE Biochemica, Creative Diagnostics., Arigo biolaboratories Corp.

Analysis of Global ELISA Tests Market report:

Global ELISA tests market is expected to rise from to an estimated value of USD 2529.97 million by 2026 registering a substantial CAGR in the forecast period of 2019-2026. This rise in the market can be attributed to rising prevalence of cancer, rising ageing population and technological advancements.

Definition:

ELISA Tests (Enzyme Linked Immunosrbent Assay) is a test that identifies detects and measures antibodies, proteins, peptides, hormones in the biological samples. It serves as a diagnostic tool detecting whether sample has antibodies that are related to a particular infectious condition. ELISA is a biochemical reaction in which antigen is adsorbed on a solid surface. ELISA test is used extensively in the diagnosis of HIV, varicella-zoster virus, which causes chickenpox and shingles, rotavirus, Zika virus, syphilis, pregnancy tests, in the measurement of cytokine, soluble proteins etc. ELISA is mostly used as screening device prior to in-depth tests.

Get Sample Copy of Report Here: @ https://www.databridgemarketresearch.com/request-a-sample/?dbmr=global-elisa-tests-market

Leading Key players profiled in this report are:

Few of the major market competitors currently working in the ELISA tests market are Ortho Clinical Diagnostics, Thermo Fisher Scientific, ZEUS Scientific, Inc., ALPCO, BD, Bio-Rad Laboratories, Inc., bioMérieux SA, Enzo Life Sciences, Inc., Merck KGaA,  BioLegend, Inc., LOEWE Biochemica GmbH, Creative Diagnostics., Arigo biolaboratories Corp., ELISA Technologies, Inc., RayBiotech, Inc., R&D Systems, Inc., AESKU.GROUP GmbH & Co. KG, Cell Technology., Arbor Assays, Eurofins Scientific and Biogenuix amongst others.

Market Drivers

·        The rising prevalence of cancer due to unhealthy lifestyle, lack of exercise and increased consumption of drugs and alcohol, would foster the growth of enzyme-linked immunosorbent assay (ELISA) testing market

·        Rising expenditure in R&D activities in the drug discovery market would boost the growth of this market

·        Rising ageing population enhances the growth of this market as they are more prone to communicable and non-communicable diseases such as cardiovascular disease, lung disease, and cancer, which drives the demand for the prevention, diagnosis, and treatment of such diseases

·       Advancements in technology and automations in the healthcare industry would drive the growth of this market

Market Restraints

·        Lack of availability and cost-effective diagnostic tests hinders the growth of this market.

·        Substitution by new technologically advanced techniques including multiplex proteomic array platforms would restrain its growth

Global ELISA Tests Market Segmentation:

By Test Type

·        Direct ELISA

·        Sandwich ELISA

·        Indirect ELISA

·        Multiple & Portable ELISA

·        Competitive ELISA

By Application

·        Immunology

·        Inflammation

·        Diagnostics

·        Vaccine Development

·        Toxicology

·        Drug Monitoring & Pharmaceutical Industry

·        Transplantation

·        Infectious Diseases

·        Cancer

·        Protein Quantitation

·        Other

By Technology

·        Chemiluminescent

·        Colorimetric

·        Fluorescent

By End-User

·        Hospitals & Diagnostic Centers

·        Research Laboratories

By Geography

·        North America

·        South America

·        Europe

·        Asia-Pacific

Company Share Analysis:

Global ELISA tests market is highly fragmented and the major players have used various strategies such as new product launches, expansions, agreements, joint ventures, partnerships, acquisitions, and others to increase their footprints in this market. The report includes market shares of ELISA tests market for global, Europe, North America, Asia-Pacific, South America and Middle East & Africa.

Get 20% Extra Discount for Early Buyer, Know More @ https://www.databridgemarketresearch.com/inquire-before-buying/?dbmr=global-elisa-tests-market

The Global ELISA Tests Market report provides the global market size of the main players in each region. Moreover, the report provides knowledge of the leading markets players within the Global ELISA Tests Market. The industry changing factors for the market segments are explored in this report.  This analysis report covers the growth factors of the worldwide market based on end-users. Market opportunities and recommendations for new investments are also encompassed in this report.

Get Customization and Discount on Report by emailing sopan.gedam@databridgemarketresearch.com . We are content with our glorious 99.9 % client satisfying rate.

Access Full Report :- https://www.databridgemarketresearch.com/reports/global-elisa-tests-market

About Us:

Data Bridge Market Research set forth itself as an unconventional and neoteric Market research and consulting firm with unparalleled level of resilience and integrated approaches. We are determined to unearth the best market opportunities and foster efficient information for your business to thrive in the market. Data Bridge Market Research provides appropriate solutions to the complex business challenges and initiates an effortless decision-making process.

Data Bridge adepts in creating satisfied clients who reckon upon our services and rely on our hard work with certitude.

Contact:

Data Bridge Market Research

+1-888-387-2818

Find More Reports Related To This Category

Global Nanomedicine Market

Global Chronic Idiopathic Constipation Treatment Market

[dbmronkar08]

Global ELISA Tests Market is Booming Market to Rapidly Growing $2529.27 million by 2026 with Top Key Players Ortho Clinical Diagnostics, Thermo Fisher Scientific, ZEUS Scientific,  ALPCO, Bio-Rad Laboratories, bioMérieux, Merck KGaA,  BioLegend, LOEWE Biochemica, Creative Diagnostics., Arigo biolaboratories Corp.

Analysis of Global ELISA Tests Market report:

Global ELISA tests market is expected to rise from to an estimated value of USD 2529.97 million by 2026 registering a substantial CAGR in the forecast period of 2019-2026. This rise in the market can be attributed to rising prevalence of cancer, rising ageing population and technological advancements.

Definition:

ELISA Tests (Enzyme Linked Immunosrbent Assay) is a test that identifies detects and measures antibodies, proteins, peptides, hormones in the biological samples. It serves as a diagnostic tool detecting whether sample has antibodies that are related to a particular infectious condition. ELISA is a biochemical reaction in which antigen is adsorbed on a solid surface. ELISA test is used extensively in the diagnosis of HIV, varicella-zoster virus, which causes chickenpox and shingles, rotavirus, Zika virus, syphilis, pregnancy tests, in the measurement of cytokine, soluble proteins etc. ELISA is mostly used as screening device prior to in-depth tests.

Get Sample Copy of Report Here: @ https://www.databridgemarketresearch.com/request-a-sample/?dbmr=global-elisa-tests-market

Market Drivers

·        The rising prevalence of cancer due to unhealthy lifestyle, lack of exercise and increased consumption of drugs and alcohol, would foster the growth of enzyme-linked immunosorbent assay (ELISA) testing market

·        Rising expenditure in R&D activities in the drug discovery market would boost the growth of this market

·        Rising ageing population enhances the growth of this market as they are more prone to communicable and non-communicable diseases such as cardiovascular disease, lung disease, and cancer, which drives the demand for the prevention, diagnosis, and treatment of such diseases

·       Advancements in technology and automations in the healthcare industry would drive the growth of this market

Market Restraints

·        Lack of availability and cost-effective diagnostic tests hinders the growth of this market.

·        Substitution by new technologically advanced techniques including multiplex proteomic array platforms would restrain its growth

Leading Key players profiled in this report are:

Few of the major market competitors currently working in the ELISA tests market are Ortho Clinical Diagnostics, Thermo Fisher Scientific, ZEUS Scientific, Inc., ALPCO, BD, Bio-Rad Laboratories, Inc., bioMérieux SA, Enzo Life Sciences, Inc., Merck KGaA,  BioLegend, Inc., LOEWE Biochemica GmbH, Creative Diagnostics., Arigo biolaboratories Corp., ELISA Technologies, Inc., RayBiotech, Inc., R&D Systems, Inc., AESKU.GROUP GmbH & Co. KG, Cell Technology., Arbor Assays, Eurofins Scientific and Biogenuix amongst others.

Global ELISA Tests Market Segmentation:

By Test Type

·        Direct ELISA

·        Sandwich ELISA

·        Indirect ELISA

·        Multiple & Portable ELISA

·        Competitive ELISA

By Application

·        Immunology

·        Inflammation

·        Diagnostics

·        Vaccine Development

·        Toxicology

·        Drug Monitoring & Pharmaceutical Industry

·        Transplantation

·        Infectious Diseases

·        Cancer

·        Protein Quantitation

·        Other

By Technology

·        Chemiluminescent

·        Colorimetric

·        Fluorescent

By End-User

·        Hospitals & Diagnostic Centers

·        Research Laboratories

By Geography

·        North America

·        South America

·        Europe

·        Asia-Pacific

Company Share Analysis:

Global ELISA tests market is highly fragmented and the major players have used various strategies such as new product launches, expansions, agreements, joint ventures, partnerships, acquisitions, and others to increase their footprints in this market. The report includes market shares of ELISA tests market for global, Europe, North America, Asia-Pacific, South America and Middle East & Africa.

Get 20% Extra Discount for Early Buyer, Know More @ https://www.databridgemarketresearch.com/inquire-before-buying/?dbmr=global-elisa-tests-market

The Global ELISA Tests Market report provides the global market size of the main players in each region. Moreover, the report provides knowledge of the leading markets players within the Global ELISA Tests Market. The industry changing factors for the market segments are explored in this report.  This analysis report covers the growth factors of the worldwide market based on end-users. Market opportunities and recommendations for new investments are also encompassed in this report.

Get Customization and Discount on Report by emailing sopan.gedam@databridgemarketresearch.com . We are content with our glorious 99.9 % client satisfying rate.

Access Full Report :- https://www.databridgemarketresearch.com/reports/global-elisa-tests-market

About Us:

Data Bridge Market Research set forth itself as an unconventional and neoteric Market research and consulting firm with unparalleled level of resilience and integrated approaches. We are determined to unearth the best market opportunities and foster efficient information for your business to thrive in the market. Data Bridge Market Research provides appropriate solutions to the complex business challenges and initiates an effortless decision-making process.

Data Bridge adepts in creating satisfied clients who reckon upon our services and rely on our hard work with certitude.

Contact:

Data Bridge Market Research

+1-888-387-2818

Find More Reports Related To This Category

Global Nanomedicine Market

Global Chronic Idiopathic Constipation Treatment Market

[researchindustry]

Global Induced Pluripotent Market Growth, Trends and Absolute Opportunity up to 2026

Global induced pluripotent market is expected to rise to an estimated value of USD 2.33 billion by 2026, registering a substantial CAGR in the forecast period of 2019-2026. This rise in market value can be attributed to the increasing prevalence of chronic diseases and ailments requiring the development of modern technologically advanced therapeutic options.

Key Market Competitors: Global Induced Pluripotent Market

Few of the major competitors currently working in the induced pluripotent market are Bristol-Myers Squibb Company; CELGENE CORPORATION; Astellas Pharma Inc.; Thermo Fisher Scientific; Cell Applications, Inc.; Axol Bioscience Ltd.; Organogenesis Holdings; Merck KGaA; FUJIFILM Holdings Corporation; Fate Therapeutics; KCI Licensing, Inc.; Japan Tissue Engineering Co., Ltd.; Vericel; ViaCyte, Inc.; STEMCELL Technologies Inc.; Horizon Discovery Group plc; Lonza; Takara Bio Inc.; Promega Corporation and QIAGEN.

Download PDF Sample report @ https://www.databridgemarketresearch.com/request-a-sample/?dbmr=global-induced-pluripotent-market

Induced pluripotent are a specialized form of stem cells that are extracted from either skin or blood cells, and are then modified into the pluripotent form which gives them the capability of being used for the treatment where any different kind of human cells are required. In the pluripotent form, they can be modified to any kind of cell form that is utilized for the treatment of different diseases/disorders.

Competitive Analysis: Global Induced Pluripotent Market

Global induced pluripotent market is highly fragmented and the major players have used various strategies such as new product launches, expansions, agreements, joint ventures, partnerships, acquisitions, and others to increase their footprints in this market. The report includes market shares of induced pluripotent market for global, Europe, North America, Asia-Pacific, South America and Middle East & Africa.

Market Segmentation: Global Induced Pluripotent Market

·         By Product Category (Cell Culture, Differentiation, Reprogramming, Engineering, Cell Analysis, Others)

·         By Cell Type (Hepatocytes, Fibroblasts, Keratinocytes, Amniotic Cells, Neurons, Others)

·         By Application (Drug Development, Regenerative Medicine, Toxicity Testing, Academic Research, Stem Cell Bio-Banking)

·         By End-User (Academic & Research Institutes, Biotechnology Companies, Hospitals)

·         By Geography (North America, South America, Europe, Asia-Pacific, Middle East and Africa)

Speak to Analyst @ https://www.databridgemarketresearch.com/speak-to-analyst/?dbmr=global-induced-pluripotent-market

Market Drivers

·         Rise in the expenditure incurred by various private and government sources on R&D is expected to drive the growth of the market

·         High levels of understanding and awareness regarding the composition of the iPSC (Induced Pluripotent Stem Cell) has resulted in a rise of demand of the product from various end-users; this factor is expected to drive the growth of the market

·         Utilization of these cells for the creation of customized tissues and helping in understanding of human development; this factor is expected to drive the growth of the market

Market Restraints

·         Complications and large costs associated with the development and manufacturing of these products are expected to restrain the growth of the market

·         Chances of health risks due to the acceptance of these products in the recipient’s body along with lack of efficiency in the process are factors restraining the growth of the market

Reasons to Purchase this Report

·         Current and future of global induced pluripotent market outlook in the developed and emerging markets

·         The segment that is expected to dominate the market as well as the segment which holds highest CAGR in the forecast period

·         Regions/Countries that are expected to witness the fastest growth rates during the forecast period

·         The latest developments, market shares, and strategies that are employed by the major market players

Customization of the Report:

·         All segmentation provided above in this report is represented at country level

·         All products covered in the market, product volume and average selling prices will be included as customizable options which may incur no or minimal additional cost (depends on customization)

Browse full report @ https://www.databridgemarketresearch.com/reports/global-induced-pluripotent-market

About Us:

Data Bridge Market Research set forth itself as an unconventional and neoteric Market research and consulting firm with unparalleled level of resilience and integrated approaches. We are determined to unearth the best market opportunities and foster efficient information for your business to thrive in the market.

Contact:

Data Bridge Market Research

Tel: +1-888-387-2818

Email: Sopan.gedam@databridgemarketresearch.com

 Related Reports:

 Global Chronic Idiopathic Constipation Treatment Market

 Global Diabetic Gastroparesis Treatment Market

[soumyafwr]

Chronic Idiopathic Constipation Treatment Market 

[martynnx-blog]

Constipation Treatment Industry Key Manufacturers Analysis with Sales, Price, Revenue, Gross Margin Forecasts To 2026

Constipation Treatment Market Overview

Constipation is a disorder that causes issues related to clearing of the bowels and usually leads to hardened feces. It is especially prevalent among the elderly and women. Common symptoms of constipation include lumpy or hard stools, lower abdominal discomfort, straining to have bowel movements, feeling of blockage in rectum that prevents bowel movements, and infrequent bowel movements. Factor that can lead to constipation are aging, dehydration, little or no physical activity, diet low in fiber, and mental conditions such as depression or eating disorder. Constipation treatment starts with lifestyle and change in diet to increase the speed at which stool moves through intestines. If it doesn’t help then the physician recommend medications or surgery. Lifestyle and diet change includes increase in fiber intake and physical activities such as exercise to increase intestinal muscle activities.

Segmentation of Constipation Treatment Market

Constipation treatment market is segmented on the basis of type, treatment, method of administration, and end use. By type, the global constipation treatment market has been categorized into chronic idiopathic constipation (CIC), irritable bowel syndrome with constipation (IBS-C), and opioid-induced constipation (OIC). On the basis of treatment, the global constipation treatment market has been categorized into pharmacological treatment and non-pharmacological treatment, which comprises bowel training for constipation relief, fluid intake, dietary fiber intake and regular exercise.

Ask For Discount Before Purchasing This Business Report @ https://www.coherentmarketinsights.com/insight/request-discount/95

High prevalence rate in North America drive growth of the Constipation Treatment Market

High prevalence rate in North America due to increasing adoption of unhealthy lifestyle characterized by growing consumption of fast food is leading to increasing obesity and other related health issues. This inadvertently leads to high incidence rate of constipation in the region.

Global players engaged in the constipation treatment market

The major players operating in constipation treatment market include AstraZeneca plc, Takeda Pharmaceutical Company Limited, Abbott Laboratories, Valeant Pharmaceuticals International, Inc., C.B. Fleet Company Inc., Daewoong Co. Ltd., Sucampo Pharmaceuticals Inc., Cosmo Pharmaceuticals, Synergy Pharmaceuticals Inc. Boehringer Ingelheim GmbH, and Ironwood Pharmaceuticals.

[kritikarehani]

Functional Constipation Market Size, Share, Trends, Epidemiology and Market Forecast 2030

DelveInsight launched a new report on “Functional Constipation - Market Insights, Epidemiology, and Market Forecast-2030”.

The report delivers an in-depth understanding of the Functional Constipation, historical and forecasted epidemiology as well as the Functional Constipation market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

Functional Constipation Overview

Traditional constipation is defined as three or fewer bowel movements per week. Risk factors for constipation include female gender, aging, inactivity, low calorie diets, low fiber diets, low income, low level of education, and high doses of medication. Chronic constipation is considered functional (primary) or secondary.

Functional constipation, also known as chronic idiopathic constipation, is found when a person experiences symptoms of constipation, but no specific cause of the problem can be identified. Because a physiological cause may be found to explain the symptoms, active constipation is one of the most common gastrointestinal disorders (FGDs).Functional constipation can be divided into normal transit, slow transit, or outlet constipation.

Click here to know more on Functional Constipation Market.

Functional Constipation Causes

Constipation is due to the slow flow of sewage (faeces) to the colon. Many of the causes include risk factors, such as inadequate hydration and dietary fiber, dysfunction, pregnancy, later travel, and stress, to critical conditions, such as intestinal obstruction due to colon cancer. Constipation is usually harmless and is due to lifestyle changes. Medications such as painkillers containing narcotics, antihistamines, and other anti-depressants are other common causes.

Functional Constipation Signs and Symptoms

Functional constipation (FC) is defined as "persistent symptoms of severe, abnormal, or seemingly incomplete exercise". Some signs and symptoms are:

●       Three or fewer bowel movements per week.

●       Heavy, cluttered stools.

●       Feeling of an incomplete discharge.

●       Sensation of obstruction in the anus and / or rectum.

●       Straining during bowel movement.

●       Finger use to help defecate (digital extraction)

●       Comfortable stools are not uncommon without the use of laxatives.

●       Abdominal pain or discomfort,

●       Bloating,

●       Gas pain,

●       Vomiting,

●       Blood in the stool,

●       Anemia,

Functional Constipation Treatment

Functional constipation treatment involves incompatibility with oral or rectal medication. Polyethylene glycol is effective and well tolerated, but there are alternatives available. After inactivity, a maintenance plan may be needed for months depending on the age because recurrence of active constipation is common. Possible causes of secondary chronic constipation include medication use, as well as medical conditions, such as hypothyroidism or irritable bowel syndrome.

Functional Constipation Market

The strength of the Functional Constipation treatment paradigm is a major obstacle where the exact cause is unknown due to the impossibility of determining the specific treatment of the index. Although there are several approved drugs for Functional Constipation, there is still a need to develop targeted therapies.

There are certain types of laxatives available on the market, and they are usually prescribed by doctors such as Bulking Laxatives, Osmotic Laxatives, and Stimulant Laxatives. Patients with FC are often initiated in the manufacture of fiber as a powerful treatment by combining fibers and bulking laxatives such as psyllium husk, bran, etc.

Request for sample pages of the report.

Functional Constipation Epidemiology Insights

●       According to ADA Health, eight million people in the US seek treatment for constipation each year, and one million are hospitalized. It is possible that many people with FC do not report this condition to doctors because they are ashamed or do not see it as a major problem that requires medical attention.

●       According to a study, out of 100 papers examined, 45 reported an increase in FC in 41 different study subjects, containing 261,040 studies. The combined increase in FC for all subjects was 14%. They also found that the prevalence of FC was higher for women and increased with age and with lower socio-economic status.

●       According to a study the increase in FC is increasing with age, with higher rates reported in older adults.

●       A study stated that FC in patients led to an increase of 16.7% and 14.9% in the Roman study. These rates were significantly higher than the prevalence rates of 4 to 5 percent observed in a larger U.S. population survey but similar to the 19.9% ​​reported in middle-aged residents in Olmsted County.

Functional Constipation Key Pharma Players:

Takeda

Allergan

Synergy Pharmaceuticals

Takeda Pharmaceuticals

Functional Constipation Pipeline Drugs:

Motegrity

Linzess

Trulance

Amitiza

Visit our repository of reports: https://www.delveinsight.com/report-store.php

[gopriyu-blog]

Global Opioid Induced Constipation Drug Market

Global Opioid Induced Constipation Drug Market was valued at US$ 2.1Bn in 2017 and is expected to reach US$ 3.2Bn by 2026 at a CAGR of 5.4%.

 The objective of the report is to present a comprehensive assessment of the market and contains thoughtful insights, facts, historical data, industry-validated market data and projections with a suitable set of assumptions and methodology. The report also helps in understanding the global opioid induced constipation drug market dynamics, structure by identifying and analysing the market segments and project the global market size. Further, the report also focuses on the competitive analysis of key players by product, price, financial position, product portfolio, growth strategies, and regional presence. The report also provides PEST analysis, PORTER’s analysis, and SWOT analysis to address questions of shareholders to prioritizing the efforts and investment in the near future to the emerging segment in the global opioid induced constipation drug market.

 Global Opioid Induced Constipation Drug Market

 The number of patients suffering from opioid induced constipation is growing across the globe. Close to 100 mn U.S. patients in 2013 were suffering from opioid induced constipation, according to the American Academy of Pain Medicine. They added that this number is anticipated to increase as the number of people consuming opioid drugs increases. With an increasing awareness of the commercial availability of a large type of opioid drugs, people have resorted to using them for longer terms to treat chronic pains.

 Increasing incidences of diseases associated with old age, impaired body functions, and rise in the use of medicines such as antidepressants and anticholinergic have collectively led to a high prevalence of constipation among the elderly population. This drives growth in the opioid induced constipation market globally. The use of laxatives for opioid induced constipation is a major challenge that is reducing sales of approved drugs meant for the treatment of opioid induced constipation.

 Lubiprostone segment is leading the global opioid induced constipation drug market. Lubiprostone under the brand name Amitiza is indicated for treating opioid induced constipation drug, where it major indication is for chronic idiopathic constipation (CIC). Lubiprostone is projected that the segment will take over the market share of methylnaltrexone bromide. Moreover, naloxegol is expected to grow at highest CAGR over the forecast period. The drug is under testing for many patient types such as pregnant women and patients less than 17 years of age. So, future approvals are expected to lead the market.

 Region-wise, North America is the dominant regional opioid induced constipation drugs market through the forecast period. Early bird approval of opioid induced constipation drugs by the USFDA and high consumption of opioids in the US is the prime growth factors for the opioid induced constipation drugs market in North America. Besides, Germany, UK, and Spain are the major countries setting the market dynamics in Europe. Overall, the developed countries across the world, predominantly North America and Europe are the key consumers of opioid induced constipation drugs.

Scope of Global Opioid Induced Constipation Drug Market

 Global Opioid Induced Constipation Drug Market, by Drug type

 • Methylnaltrexone Bromide

• Lubiprostone

• Naloxegol

• Naldemedine

• Docusate Sodium

• Others

Global Opioid Induced Constipation Drug Market, by Prescription type

 • Prescribed

• Over The Counter

Global Opioid Induced Constipation Drug Market, by Region

 • North America

• Europe

• Asia Pacific

• Middle East and Africa

• South America

Key players operating in Global Opioid Induced Constipation Drug Market

 • GlaxoSmithKline, Inc.

• AstraZeneca plc, Inc.

• Pfizer, Inc.

• S.L.A. Pharma AG

• AIKO Biotechnology

• Cubist Pharmaceuticals

• Salix Pharmaceuticals, Inc.

• Takeda Pharmaceutical Company Limited

   This Report Is Submitted By Maximize Market Research

Customization of the report:

Maximize Market Research provides free personalized of reports as per your demand. This report can be personalized to meet your requirements. Get in touch with us and our sales team will guarantee provide you to get a report that suits your necessities.

About Maximize Market Research:

Maximize Market Research provides B2B and B2C research on 20,000 high growth emerging opportunities & technologies as well as threats to the companies across the Healthcare, Pharmaceuticals, Electronics & Communications, Internet of Things, Food and Beverages, Aerospace and Defense and other manufacturing sectors.

Contact info:

Name: Lumawant Godage

Organization: MAXIMIZE MARKET RESEARCH PVT. LTD.

Email: sales@maximizemarketresearch.com

Address: Maharashtra 411051, India.

[coolluminaryland-blog1]

Constipation Treatment Market: Industry Players Introduce Key Business Strategies to Advertise their Products

Global Constipation Treatment Market: Snapshot

The demand in the global market for constipation treatment is projected to increment at a healthy CAGR of 7.1% during the forecast period of 2017 to 2025. This prosperity of the constipation treatment market is primarily a reflection of escalating geriatric population across the globe, as people aged over 50 years are highly prone to irregular bowel movement. Consistent research and development to develop novel drugs that are more efficient, improving healthcare infrastructure in various emerging economies, and growing awareness among the end-users are some of the other factors favoring the global constipation treatment market. On the other hand, continued reliance of the patients on over-the-counter drugs and vast unmet demands in rural areas of developing countries is hindering the proper prosperity of the global constipation treatment market. Evaluated to have a worth of US$12.58 bn in 2016, the global constipation treatment market is estimated to reach a valuation of US$22.93 bn by the end of the forecast period, which is 2025.

Request A Sample: https://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=16442

Laxatives Remain Highly Profitable Therapeutic Segment

On the basis of therapeutic option, the global market for constipation treatment is segmented into laxatives, peripherally acting mu opioid receptor antagonists, chloride channel activators, GC-C agonists, and 5-HT4 receptor agonists. In 2016, the laxatives segment, which is further categorized into bulk forming agents, stimulant laxatives, and osmotic laxatives, accounted for the maximum demand-share. Over the course of the forecast period, the laxatives segment is anticipated to be most promising and dominate the market share. Affordability for the masses owing to low cost and wide availability are two key factors leading to the prosperity of this laxatives segment. That being said, GC-C agonists segment is projected for the best CAGR of 8.7% from 2017 to 2025.

Based on the type of disease, the global constipation treatment market is bifurcated into irritable bowel syndrome with constipation, chronic idiopathic constipation, and opioid induced constipation. The opioid induced constipation segment is projected to expand at CAGR of 7.5% during the forecast period from 2017 to 2025. Based on distribution channel, global market is classified into hospital pharmacies, retail pharmacies, and online pharmacies. Retail pharmacies segment is projected to hold major share of global constipation treatment market in the near future.

Request Brochure of Report: https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=16442

Asia Pacific Projected for Most Impressive Growth Rate

Geographically, the global constipation treatment market has been classified into six major regions, viz. North America, Asia Pacific, Europe, Latin America, The Middle East & Africa, and Commonwealth of Independent States. In 2017, North America served the maximum demand in the constipation treatment market, owing to high prevalence of chronic constipation, high per capita healthcare expenditure, and availability of specialty constipation medicines. The North America constipation market is estimated to be worth US$9.98 bn by the end of 2025. Europe currently is second most lucrative region for the vendors operating in this market, however, Asia Pacific is anticipated to turn into a region-of-focus, with its considerably established market in emerging economies. Japan, India, and China are identified as three emerging country-wide markets for constipation treatment.

Some of the key players currently holding a position of strength in the global constipation market are: Bayer AG, Ironwood Pharmaceuticals, Inc., Takeda Pharmaceuticals Company Limited, Sanofi, AstraZeneca, Abbott Laboratories, Sucampo Pharmaceuticals, Inc., Synergy Pharmaceuticals, Inc., Valeant Pharmaceuticals International, Inc., Valeant Pharmaceuticals International, Inc., Janssen Pharmaceutical Company, Daewoong Pharmaceuticals Co. Ltd., Prestige Brands Holdings, Inc., Shionogi & Co., Ltd., Renexxion, LLC., Albireo Pharma, Inc., and Cosmo Pharmaceuticals NV.

About us:

Transparency Market Research (TMR) is a U.S.-based provider of syndicated research, customized research, and consulting services. TMR’s global and regional market intelligence coverage includes industries such as pharmaceutical, chemicals and materials, technology and media, food and beverages, and consumer goods, among others. Each TMR research report provides clients with a 360-degree view of the market with statistical forecasts, competitive landscape, detailed segmentation, key trends, and strategic recommendations.

Contact us:

Transparency Market Research 90 State Street, Suite 700, Albany NY – 12207 United States Tel: +1-518-618-1030 USA – Canada Toll Free 866-552-3453 Email: sales@transparencymarketresearch.com Website: http://www.transparencymarketresearch.com/

[dbmronkar]

Global ELISA Tests Market is Booming Market to Rapidly Growing $2529.27 million by 2026 with Top Key Players Ortho Clinical Diagnostics, Thermo Fisher Scientific, ZEUS Scientific,  ALPCO, Bio-Rad Laboratories, bioMérieux, Merck KGaA,  BioLegend, LOEWE Biochemica, Creative Diagnostics., Arigo biolaboratories Corp.

Definition:

ELISA Tests (Enzyme Linked Immunosrbent Assay) is a test that identifies detects and measures antibodies, proteins, peptides, hormones in the biological samples. It serves as a diagnostic tool detecting whether sample has antibodies that are related to a particular infectious condition. ELISA is a biochemical reaction in which antigen is adsorbed on a solid surface. ELISA test is used extensively in the diagnosis of HIV, varicella-zoster virus, which causes chickenpox and shingles, rotavirus, Zika virus, syphilis, pregnancy tests, in the measurement of cytokine, soluble proteins etc. ELISA is mostly used as screening device prior to in-depth tests.

Analysis of Global ELISA Tests Market report:

Global ELISA tests market is expected to rise from to an estimated value of USD 2529.97 million by 2026 registering a substantial CAGR in the forecast period of 2019-2026. This rise in the market can be attributed to rising prevalence of cancer, rising ageing population and technological advancements.

Get Sample Copy of Report Here: @ https://www.databridgemarketresearch.com/request-a-sample/?dbmr=global-elisa-tests-market

Market Drivers

·        The rising prevalence of cancer due to unhealthy lifestyle, lack of exercise and increased consumption of drugs and alcohol, would foster the growth of enzyme-linked immunosorbent assay (ELISA) testing market

·        Rising expenditure in R&D activities in the drug discovery market would boost the growth of this market

·        Rising ageing population enhances the growth of this market as they are more prone to communicable and non-communicable diseases such as cardiovascular disease, lung disease, and cancer, which drives the demand for the prevention, diagnosis, and treatment of such diseases

·       Advancements in technology and automations in the healthcare industry would drive the growth of this market

Market Restraints

·        Lack of availability and cost-effective diagnostic tests hinders the growth of this market.

·        Substitution by new technologically advanced techniques including multiplex proteomic array platforms would restrain its growth

Leading Key players profiled in this report are:

Few of the major market competitors currently working in the ELISA tests market are Ortho Clinical Diagnostics, Thermo Fisher Scientific, ZEUS Scientific, Inc., ALPCO, BD, Bio-Rad Laboratories, Inc., bioMérieux SA, Enzo Life Sciences, Inc., Merck KGaA,  BioLegend, Inc., LOEWE Biochemica GmbH, Creative Diagnostics., Arigo biolaboratories Corp., ELISA Technologies, Inc., RayBiotech, Inc., R&D Systems, Inc., AESKU.GROUP GmbH & Co. KG, Cell Technology., Arbor Assays, Eurofins Scientific and Biogenuix amongst others.

Global ELISA Tests Market Segmentation:

By Test Type

·        Direct ELISA

·        Sandwich ELISA

·        Indirect ELISA

·        Multiple & Portable ELISA

·        Competitive ELISA

By Application

·        Immunology

·        Inflammation

·        Diagnostics

·        Vaccine Development

·        Toxicology

·        Drug Monitoring & Pharmaceutical Industry

·        Transplantation

·        Infectious Diseases

·        Cancer

·        Protein Quantitation

·        Other

By Technology

·        Chemiluminescent

·        Colorimetric

·        Fluorescent

By End-User

·        Hospitals & Diagnostic Centers

·        Research Laboratories

By Geography

·        North America

·        South America

·        Europe

·        Asia-Pacific

Company Share Analysis:

Global ELISA tests market is highly fragmented and the major players have used various strategies such as new product launches, expansions, agreements, joint ventures, partnerships, acquisitions, and others to increase their footprints in this market. The report includes market shares of ELISA tests market for global, Europe, North America, Asia-Pacific, South America and Middle East & Africa.

Get 20% Extra Discount for Early Buyer, Know More @ https://www.databridgemarketresearch.com/inquire-before-buying/?dbmr=global-elisa-tests-market

The Global ELISA Tests Market report provides the global market size of the main players in each region. Moreover, the report provides knowledge of the leading markets players within the Global ELISA Tests Market. The industry changing factors for the market segments are explored in this report.  This analysis report covers the growth factors of the worldwide market based on end-users. Market opportunities and recommendations for new investments are also encompassed in this report.

Get Customization and Discount on Report by emailing sopan.gedam@databridgemarketresearch.com . We are content with our glorious 99.9 % client satisfying rate.

Access Full Report :- https://www.databridgemarketresearch.com/reports/global-elisa-tests-market

About Us:

Data Bridge Market Research set forth itself as an unconventional and neoteric Market research and consulting firm with unparalleled level of resilience and integrated approaches. We are determined to unearth the best market opportunities and foster efficient information for your business to thrive in the market. Data Bridge Market Research provides appropriate solutions to the complex business challenges and initiates an effortless decision-making process.

Data Bridge adepts in creating satisfied clients who reckon upon our services and rely on our hard work with certitude.

Contact:

Data Bridge Market Research

+1-888-387-2818

Find More Reports Related To This Category

Global Nanomedicine Market

Global Chronic Idiopathic Constipation Treatment Market

[pragya1-blog]

Constipation Treatment Market Opportunity will Rise to  US$22.93 bn by 2025

Global Constipation Treatment Market: Snapshot

The demand in the global market for constipation treatment is projected to increment at a healthy CAGR of 7.1% during the forecast period of 2017 to 2025. This prosperity of the constipation treatment market is primarily a reflection of escalating geriatric population across the globe, as people aged over 50 years are highly prone to irregular bowel movement. Consistent research and development to develop novel drugs that are more efficient, improving healthcare infrastructure in various emerging economies, and growing awareness among the end-users are some of the other factors favoring the global constipation treatment market. On the other hand, continued reliance of the patients on over-the-counter drugs and vast unmet demands in rural areas of developing countries is hindering the proper prosperity of the global constipation treatment market. Evaluated to have a worth of US$12.58 bn in 2016, the global constipation treatment market is estimated to reach a valuation of US$22.93 bn by the end of the forecast period, which is 2025.

Browse Press Release @

https://www.transparencymarketresearch.com/pressrelease/constipation-treatment-market.htm

Laxatives Remain Highly Profitable Therapeutic Segment

On the basis of therapeutic option, the global market for constipation treatment is segmented into laxatives, peripherally acting mu opioid receptor antagonists, chloride channel activators, GC-C agonists, and 5-HT4 receptor agonists. In 2016, the laxatives segment, which is further categorized into bulk forming agents, stimulant laxatives, and osmotic laxatives, accounted for the maximum demand-share. Over the course of the forecast period, the laxatives segment is anticipated to be most promising and dominate the market share. Affordability for the masses owing to low cost and wide availability are two key factors leading to the prosperity of this laxatives segment. That being said, GC-C agonists segment is projected for the best CAGR of 8.7% from 2017 to 2025.

Request for Sample Copy of Report @

https://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=16442

Based on the type of disease, the global constipation treatment market is bifurcated into irritable bowel syndrome with constipation, chronic idiopathic constipation, and opioid induced constipation. The opioid induced constipation segment is projected to expand at CAGR of 7.5% during the forecast period from 2017 to 2025. Based on distribution channel, global market is classified into hospital pharmacies, retail pharmacies, and online pharmacies. Retail pharmacies segment is projected to hold major share of global constipation treatment market in the near future.

Request Report Brochure @

https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=16442

About Us

Transparency Market Research (TMR) is a global market intelligence company providing business information reports and services. The company’s exclusive blend of quantitative forecasting and trend analysis provides forward-looking insight for thousands of decision makers. TMR’s experienced team of analysts, researchers, and consultants use proprietary data sources and various tools and techniques to gather and analyze information. Our business offerings represent the latest and the most reliable information indispensable for businesses to sustain a competitive edge.

Contact Us

Transparency Market Research State Tower, 90 State Street, Suite 700 Albany, NY 12207 United States Tel: +1-518-618-1030 USA - Canada Toll Free: 866-552-3453 Email: sales@transparencymarketresearch.com Website: www.transparencymarketresearch.com

[ahila-blog1]

Global Analysis On Chronic Idiopathic Constipation Treatment Market Based On Current Market Trends And Future Insights

 Chronic Idiopathic Constipation Treatment Market

·         The global chronic idiopathic constipation treatment market is segmented on the basis of route of administration, drug class, distribution mode and end-users

·         The report covers in-detail insights about the competitor’s overview, key findings and their key strategies

 Chronic idiopathic constipation (CIC) is a gastrointestinal disorder which is due to difficulty in defecating. Since it is chronic the symptoms are worse which include gastric pain, bloating, abdominal discomfort, hard stool, incomplete evacuation and strain during the bowel movement. Since the cause is unclear, however it can be cause due to neurological, psychological and psychosomatic conditions. It is a major problem occurring to the adults or geriatric people.

 Request Sample Report: https://bit.ly/2Q5Dogm

 Factors such as increased cases of chronic idiopathic constipation due to change in lifestyle and food habits, rise in awareness about the CIC treatment, increase in the demand for CIC drugs, and availability of the over-the-counter CIC drugs in the market are driving the CIC treatment market. Moreover, various pipeline drugs for the CIC treatment and frequent product approvals from various drug regulatory bodies are propelling the market. However, lack of physiological symptoms for the disease and less number of drugs available for CIC treatment are the factors anticipated to hinder the growth of CIC market.

The Chronic idiopathic constipation treatment market is divided into following categories-  

1.      Drug class

·         Emollients

·         Laxatives

·         Bulk-forming agents

·         Chloride channel activators

·         Osmotic products

·         Others

2.     Route of administration

·         Oral

·         Parenteral

3.      Distribution mode

·         Prescription mode

·         Over-the-counter drugs

4.     End-users

·         Hospital pharmacies

·         Retail pharmacies

·         Online pharmacies

·         Drug Stores

And lastly, on the basis of geographical regions, the global Chronic Idiopathic Constipation (CIC) treatment market is segmented into North America, Europe, Asia Pacific, Latin America, and the Middle East and Africa.

North America has a significant share in chronic idiopathic constipation treatment market owing to increased cases of CIC disease, change in lifestyle, recent FDA approvals for CIC treatment drugs, an increase in healthcare expenditure.

In Europe, increase in ageing population, rise in R&D activities for CIC treatments, availability of over-the-counter CIC drugs, an increase in per capita income might bolster the market. However, Asia-Pacific exhibiting lucrative growth owing to the rise in geriatric population, an increase in adoption of CIC treatments.

Some of the key players in CIC treatment market are GlaxoSmithKline Plc. (U.K.), Bayer AG (Germany), Allergan Plc. (Ireland), Ironwood Pharmaceuticals, Inc. (U.S.), Astellas Pharma, Inc. (Japan), Sanofi S.A. (France), and  Pfizer, Inc. (U.S.) to name a few. Some of the market developments include Astellas Pharma, Inc. submitting the Supplemental new drug application in 2017 for Linaclotide for patients with chronic idiopathic constipation in Japan. 

Acquisitions and mergers, product approvals, and product launchings are the key strategies adopted by the companies for increasing their revenue share in the market. For e.g. in 2017, FDA approved Tulane manufactured by Synergy Pharmaceuticals used in the treatment of chronic idiopathic constipation.

 Key Questions Answered

·         What is the current and future CIC market outlook worldwide? What trends are affecting the global market?

·         What is the competitive landscape and market share of major players in the chronic idiopathic constipation globally?

·         What are the key, high growth markets that CIC manufacturers should expand into? Which market segments are growing the fastest?

·         What are the unmet needs with the chronic idiopathic constipation currently on the market? How will emerging technologies fulfil these unmet needs?

·         What is physician perception and market outlook of CIC?

·         What are the challenges and barriers that have hindered widespread adoption of chronic idiopathic constipation?

Reasons to buy chronic idiopathic constipation market Report:

·         Global, regional and country-level analysis and forecasts of the study market; providing Insights on the geographical areas in which this industry is prospering

·         Segment-level analysis on basis of product type, application, colour along with market size forecasts and y-o-y estimations to detect key areas of industry growth in detail

·         Identification of key drivers, restraints, opportunities, and challenges (DROC) in the market and their impact on shifting market dynamics

·         Study of macro and micro environmental factors that affect the market presented in an extensive strategic analyses section containing PESTLE and Porter’s Five Forces Analyses

·         A comprehensive listing of key market players along with company overview, product portfolios, key financial information (subjected to availability), SWOT analysis and Analyst overview to study and sustain the market environment

·         Competitive landscape analysis listing out the mergers, acquisitions, collaborations in the field along with new product launches, comparative financial studies and recent developments in the market by the major companies

·         Expertly devised Market Outlook along with Investment opportunities to provide both individuals and organizations a strong financial foothold in the market

  For More Information : https://www.precisionbusinessinsights.com/market-reports/global-chronic-idiopathic-constipation-treatment-market/

[martynnx-blog]

Chronic Idiopathic Constipation (CIC) Treatment Market Till, 2018-2026 - New Study By Coherent Market Insights

Constipation is condition wherein the stool frequency reduces up to three times per week with difficulty in stool passing. Chronic constipation is a highly common functional gastrointestinal disorder that adversely affects patient’s life. Chronic idiopathic constipation is defined as the presence of chronic symptoms of constipation with no well-defined underlying cause. The symptoms of chronic idiopathic constipation includes infrequent bowel movements, hard stools, straining during defecation, feeling of incomplete evacuation, abdominal discomfort, and bloating sensation. Chronic idiopathic constipation is diagnosed by laboratory tests, endoscopy, radiological tests, magnetic resonance imaging, and physiological testing. Currently, very few approved treatment options are available for chronic idiopathic constipation, which is expected to be a major factor restrain growth of the chronic idiopathic constipation treatment market. However, this gives opportunity for the market player to come up with the novel treatment to grab the foothold in growing chronic idiopathic constipation treatment market.

Request Sample Copy of Research Report @ https://www.coherentmarketinsights.com/insight/request-sample/1791

Chronic Idiopathic Constipation (CIC) Treatment Market Dynamics

Increasing clinical trials and approval of drug candidates by pharmaceutical companies to fulfil unmet medical needs of the chronic idiopathic constipation treatment is a key factor driving the market growth over the forecast period. For instance, March 2018, Shire plc received new drug application from U.S. FDA for its drug candidate, SHP555 (prucalopride) for the indication of chronic idiopathic constipation in adults. Moreover, in 2015, SHP555 (prucalopride)received approval from European Commission for the symptomatic treatment of chronic constipation in adults with failure of laxative treatment. Furthermore, Renexxion is conducting phase 2 clinical trial for Naronapride (ATI-7505) for the treatment of multiple gastrointestinal disorders, which includes chronic idiopathic constipation. In 2017, FDA approved Ironwood and Allergan’s Linzess (linaclotide) for the treatment of chronic idiopathic constipation. However, 50% of patients with chronic constipation dissatisfied with their current treatment, mainly because of the lack of efficacy, which highlights a continued medical need for more effective and safer therapeutic agents.

However, the use of alternate therapy such as home-based remedies and herbal medication such as herbal laxative, probiotic foods etc. are expected to be major factors hindering the chronic idiopathic constipation treatment market growth.

Chronic Idiopathic Constipation (CIC) Treatment Market – Regional Analysis

Regional segmentation of chronic idiopathic constipation treatment market by Coherent Market Insights includes North America, Latin America, Europe, Asia Pacific, Middle East, and Africa. North America chronic idiopathic constipation treatment market holds dominant position owing to high percentage of population suffering from chronic constipation. For instance, according to European Journal of Pharmacology, 2017, in the U.S. 12%–19% of population suffers from chronic constipation. This is expected to aid in growth of the market in the region over the forecast period. However, Asia Pacific is expected to witness the fastest growth, owing to increasing prevalence of constipation in the Asian countries. According to Journal of Neurogastroenterology and Motility article 2016, in Asian countries such as China, Korea, Hong Kong, and India, the prevalence of constipation reportedly ranges from 8.2% to 16.8%. This is expected to support growth of the chronic idiopathic constipation treatment market size over the forecast period.

Chronic Idiopathic Constipation (CIC) Treatment Market – Competitive Analysis

Key players in chronic idiopathic constipation treatment market are Ironwood Pharmaceuticals, Allergan, Synergy Pharmaceuticals, Inc., Shire plc, and Mallinckrodt plc. The presence of very few market player provides wide opportunity for new entrant in chronic idiopathic constipation market. Moreover, in February 2018, Mallinckrodt plc, global specialty pharmaceutical company, announced acquisition of Sucampo Pharmaceuticals, Inc., a biopharmaceutical company. The acquisition assets includes its FDA approved blockbuster drug Amitiza (lubiprostone) for the treatment of chronic idiopathic constipation (CIC) in adults, irritable bowel syndrome with constipation (IBS-C). The Sucampo Pharmaceuticals, Inc. also partnered with Par Pharmaceuticals, Inc. and Dr. Reddy’s Laboratories Ltd. As a part of the agreement both the partners were granted a non-exclusive license to market Par’s generic version of lubiprostone in the U.S. from January, 2021. Such inorganic strategies of market players are expected to boost growth of the market significantly over the forecast period. In 2012, Ferring Pharmaceuticals acquired the rights for development and commercialization of Elobixibat, first-in-class compound for chronic idiopathic constipation from Albireo AB, a Swedish biotechnology company. Further, in 2013, Ferring Pharmaceuticals, initiated phase III clinical trials of Elobixibat.

Inquire Here Before Purchase of Research Report @ https://www.coherentmarketinsights.com/insight/talk-to-analyst/1791